Cost effectiveness of interferon-γ release assay for tuberculosis contact screening in Japan

Molecular Diagnosis and Therapy

Volumn 12, Issue 4, 2008, Pages 235-251

  Kowada, Akiko ^a   Takahashi, Osamu ^b   Shimbo, Takuro ^c   Ohde, Sachiko ^d   Tokuda, Yasuharu ^b   Fukui, Tsuguya ^b  

^a Katsushika City Public Health Center   (Japan)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c Center for Clinical Epidemiology St Luke's Life Science Institute   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Cost effectiveness; Diagnostics; Disease prevention; Markov model; Screening; Tuberculosis

Indexed keywords

GAMMA INTERFERON; ISONIAZID; BCG VACCINE; DIAGNOSTIC AGENT; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; CROSS REACTION; CYTOKINE RELEASE; HUMAN; IMMUNOASSAY; IMMUNOCOMPETENCE; JAPAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROTEIN DETERMINATION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; TUBERCULIN TEST; UNSPECIFIED SIDE EFFECT; AGED; BLOOD; CONTACT EXAMINATION; COST BENEFIT ANALYSIS; ECONOMICS; HETEROZYGOTE; LABORATORY DIAGNOSIS; MASS SCREENING; METHODOLOGY; MIDDLE AGED; THEORETICAL MODEL; TUBERCULOSIS;

MYCOBACTERIUM BOVIS BCG;

ADULT; AGED; ANTITUBERCULAR AGENTS; BCG VACCINE; CARRIER STATE; CONTACT TRACING; COST-BENEFIT ANALYSIS; FALSE POSITIVE REACTIONS; HUMANS; INTERFERON TYPE II; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 53749103222     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256289     Document Type: Article

References (43)

1. World Health Organization. Global tuberculosis control: surveilance, planning, financing. WHO Report 2007; WHO/HTM/TB/2007.376 [online]. Available from URL: http://www.who.int/tb/publications/global_report/2007/en/ [Accessed 2008 Apr 22]
2. Health Labour and Welfare Ministry. Epidemiology of tuberculosis in Japan [in Japanese]. Tokyo: Health Labour and Welfare Ministry, 2007
3. Macintyre CR, Plant AJ, Hendrie D. The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis. Health Econ 2000; 9 (5): 411-21
4. Diel R, Nienhaus A, Lange C, et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28 (1): 35-44
5. Mori T, Harada N. Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations [in Japanese]. Kekkaku 2005; 80 (11): 675-86
6. The National Tuberculosis Controllers Association and CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005 Dec 16; 54 (RR-15): 1-47 [online]. Available from URL: http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf [Accessed 2008 Apr 22]
7. Kowada A, Hamada Y, Aoki M. Utility of QuantiFERON TB-2G for tuberculosis contact investigations in public health services [in Japanese]. Nippon Koshu Eisei Zasshi 2007; 54 (7): 434-9
8. Diel R, Zaslavsky AM, Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007; 131 (5): 1424-34
9. Diel R, Wrighton-Smith P, Zellweger JP. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J 2007 Aug; 30 (2): 321-32
10. Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54 (RR-15): 49-55
11. Health Labour and Welfare Ministry. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Tokyo: Health Labour and Welfare Ministry, 2007 [in Japanese; online]. Available from URL: http://www.phcd.jp/shiryo/TB/2007TBsesshokusha_kenshin_tebiki_2han.pdf [Accessed 2008 May 21]
12. Health Labour and Welfare Ministry. Guidelines for preventing the transmission of mycobacterium tuberculosis in health-care settings [in Japanese]. Tokyo: Health Labour and Welfare Ministry, 1999
13. Life table in Japan, 2005 [in Japanese; online]. Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/life/20th/index.html [Accessed 2008 May 21]
14. Research Institute of Tuberculosis in Japan. Research project for surveillance [in Japanese]. Tokyo: Research Institute of Tuberculosis in Japan, 2006
15. Jereb J, Etkind SC, Joglar OT, et al. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003; 7 (12 Suppl. 3): S384-90
16. Tokyo Metropolitan Government. Tuberculosis in Tokyo [in Japanese]. Tokyo: Health and Safety Office Bureau of Welfare and Public Health, 2005
17. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368 (9553): 2142-54
18. Tuberculosis Research Committee (Ryoken). Drug-resistant Mycobacterium tuberculosis in Japan: a nationwide survey, 2002. Int J Tuberc Lung Dis 2007 Oct; 11 (10): 1129-35
19. Horsburgh Jr CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350 (20): 2060-7
20. Kimura M, Comstock GW, Mori T. Comparison of erythema and induration as results of tuberculin tests. Int J Tuberc Lung Dis 2005; 9 (8): 853-7
21. Yoshiyama T. Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings [in Japanese]. Kekkaku 2000; 75 (11): 629-41
22. Yoshiyama T, Ogata H, Wada M. Treatment results of multi drug resistant tuberculosis, a hospital based study [in Japanese]. Kekkaku 2005; 80 (11): 687-93
23. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146 (5): 340-54
24. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170 (1): 59-64
25. Ito K, Hoshino H, Nakazono T, et al. Liver damage in treatment of latent tuberculous infection by isoniazid [in Japanese]. Kekkaku 2006; 81 (11): 651-60
26. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128 (1): 116-23
27. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168 (4): 443-7
28. Miyashita H, Higuchi K, Higashiyama N, et al. Detection of tuberculosis infection using a whole blood interferon gamma assay in a contact investigation: evaluation using quantiFERon TB-2G [in Japanese]. Kekkaku 2005; 80 (8): 557-64
29. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 2005; 26 (3): 465-73
30. Moran-Mendoza O, Marion SA, Elwood K, et al. Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts. Int J Tuberc Lung Dis 2007; 11 (9): 1014-20
31. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10 (11): 1192-204
32. Igakutsushin-sha. Medical insurance reimbursement table in Japan [in Japanese]. Tokyo: Igakutsushin-sha, 2007 [online]. Available from URL: http://igakutushin.co.jp/index1.php?contenturl=page1.php?sid=299 [Accessed 2008 May 21]
33. Kang YA, Choi YJ, Cho YJ, et al. Cost of treatment for multidrug-resistant tuberculosis in South Korea. Respirology 2006; 11 (6): 793-8
34. Health Labour and Welfare Ministry. Basic survey on wage structure in Japan [in Japanese]. Tokyo: Health, Labour and Welfare Ministry, 2006
35. Statistics Bureau. Japan statistical yearbook 2007 [in Japanese]. Tokyo: Ministry of Internal Affairs and Communications, 2007
36. Organisation for Economic Co-operation and Development. Purchasing power parities data. Organisation for Economic Co-operation and Development, 2007 [in Japanese; online]. Available from URL: http://www.oecd.org/dataoecd/61/56/ 39653523.xls [Accessed 2008 Apr 22]
37. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276 (15): 1253-8
38. Arend SM, Thijsen SF, Leyten EM, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007; 175 (6): 618-27
39. Funayama K, Tsujimoto A, Mori M, et al. Usefulness of QuantiFERON TB-2G in contact investigation of a tuberculosis outbreak in a university [in Japanese]. Kekkaku 2005; 80 (7): 527-34
40. Health Labour and Welfare Ministry. Interferon-gamma release assay as tuberculosis screening test in Japan [in Japanese; online]. Available from URL: http://www.toyama.med.or.jp/kaiin/tuti/kensaryou.pdf [Accessed 2008 May 21]
41. Research Institute of Tuberculosis in Japan. Tuberculosis reaction surveillance [in Japanese]. Tokyo: Research Institute of Tuberculosis in Japan, 1999
42. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11 (1): 16-26
43. TB guidelines [in Japanese; online]. Available from URL: http://www.cdc.gov/TB/pubs/mmwr/Maj_guide/cdc_ats_guidelines.htm [Accessed 2008 Apr 23]